Display options
Cite
Robinson GW, Kaste SC, Chemaitilly W, et al. Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. Oncotarget. 2017;8(41):69295-69302doi: 10.18632/oncotarget.20619.
Robinson, G. W., Kaste, S. C., Chemaitilly, W., Bowers, D. C., Laughton, S., Smith, A., Gottardo, N. G., Partap, S., Bendel, A., Wright, K. D., Orr, B. A., Warner, W. C., Onar-Thomas, A., & Gajjar, A. (2017). Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. Oncotarget, 8(41), 69295-69302. https://doi.org/10.18632/oncotarget.20619
Robinson, Giles W, et al. "Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor." Oncotarget vol. 8,41 (2017): 69295-69302. doi: https://doi.org/10.18632/oncotarget.20619
Robinson GW, Kaste SC, Chemaitilly W, Bowers DC, Laughton S, Smith A, Gottardo NG, Partap S, Bendel A, Wright KD, Orr BA, Warner WC, Onar-Thomas A, Gajjar A. Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. Oncotarget. 2017 Sep 01;8(41):69295-69302. doi: 10.18632/oncotarget.20619. eCollection 2017 Sep 19. PMID: 29050204; PMCID: PMC5642479.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Sep 01;8(41):69295-69302. doi: 10.18632/oncotarget.20619. eCollection 2017 Sep 19.

Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor.

Oncotarget

Giles W Robinson, Sue C Kaste, Wassim Chemaitilly, Daniel C Bowers, Stephen Laughton, Amy Smith, Nicholas G Gottardo, Sonia Partap, Anne Bendel, Karen D Wright, Brent A Orr, William C Warner, Arzu Onar-Thomas, Amar Gajjar

Affiliations

  1. Department of Oncology, Division of Neuro-Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  2. Department of Radiological Sciences, Division of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN, USA.
  3. Department of Pediatric Medicine, Division of Endocrinology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  4. Division of Pediatric Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  5. Starship Blood and Cancer Centre, Starship Children's Hospital, Auckland, NZ, USA.
  6. Division of Pediatric Hematology/Oncology, The Haley Center for Children's Cancer and Blood Disorders at Arnold Palmer Hospital, Orlando, FL, USA.
  7. Department of Haematology and Oncology, Princess Margaret Hospital for Children, School of Paediatrics and Child Health, Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia.
  8. Department of Neurology, Division of Child Neurology, Lucile Packard Children's Hospital at Stanford, Stanford University, Palo Alto, CA, USA.
  9. Cancer and Blood Disorders Program, Children's Hospitals and Clinics of Minnesota, Minneapolis, MN, USA.
  10. Pediatric Medical Neuro-Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.
  11. Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  12. Department of Orthopedic Surgery, Campbell Clinic, University of Tennessee College of Medicine, Germantown, TN, USA.
  13. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA.

PMID: 29050204 PMCID: PMC5642479 DOI: 10.18632/oncotarget.20619

Abstract

The permanent defects in bone growth observed in preclinical studies of hedgehog (Hh) pathway inhibitors were not substantiated in early phase clinical studies of vismodegib in children. Consequently, vismodegib advanced into pediatric trials for malignancies suspected of being driven by aberrant activation of the Hh pathway. In one multicenter phase II trial, vismodegib was added to the therapy regimen for newly diagnosed Hh pathway activated medulloblastoma. Herein, we report on 3 children (2 on trial and one off trial) treated with vismodegib who developed widespread growth plate fusions that persist long after cessation of therapy. Currently, all 3 patients exhibit profound short stature and disproportionate growth, and 2 subsequently developed precocious puberty. Notably, the growth plate fusions only developed after a prolonged exposure to the drug (> 140 days). These findings resulted in a major trial amendment to restrict the agent to skeletally mature patients as well as a product label warning and update. Moreover, these findings alter the risk-benefit ratio of Hh inhibitors and underscore the importance of careful study of targeted agents in children.

Keywords: childhood toxicity; hedgehog inhibitor; medulloblastoma; premature physeal fusion; targeted therapy

Conflict of interest statement

CONFLICTS OF INTEREST The authors have no conflicts of interest to declare.

References

  1. Neuro Oncol. 2015 Jan;16 Suppl 10:x1-x36 - PubMed
  2. Cancer Cell. 2008 Mar;13(3):249-60 - PubMed
  3. Pediatr Blood Cancer. 2016 Nov;63(11):2058 - PubMed
  4. Dev Cell. 2016 Aug 22;38(4):333-44 - PubMed
  5. Clin Cancer Res. 2013 Nov 15;19(22):6305-12 - PubMed
  6. BMC Pediatr. 2014 Sep 22;14:236 - PubMed
  7. J Natl Cancer Inst. 2009 Jul 1;101(13):946-58 - PubMed
  8. Science. 2004 Jun 18;304(5678):1755-9 - PubMed
  9. J Clin Oncol. 2008 Mar 1;26(7):1112-8 - PubMed
  10. Cold Spring Harb Perspect Biol. 2017 May 1;9(5): - PubMed
  11. N Engl J Med. 2009 Sep 17;361(12 ):1173-8 - PubMed
  12. J Clin Endocrinol Metab. 2003 Oct;88(10):4677-81 - PubMed
  13. Cancer Cell. 2004 Sep;6(3):229-40 - PubMed
  14. J Clin Oncol. 2015 Aug 20;33(24):2646-54 - PubMed
  15. Nat Rev Clin Oncol. 2014 Dec;11(12):714-22 - PubMed
  16. Neuro Oncol. 2017 Oct 19;19(11):1542-1552 - PubMed
  17. N Engl J Med. 2012 Jun 7;366(23):2171-9 - PubMed
  18. Am J Hum Genet. 2003 Apr;72(4):1040-6 - PubMed
  19. Nature. 2003 May 15;423(6937):332-6 - PubMed
  20. Genes Dev. 2008 Sep 15;22(18):2454-72 - PubMed
  21. Acta Neuropathol. 2012 Apr;123(4):473-84 - PubMed

Publication Types